Knight Therapeutics (KHTR.F) Stock Overview
Focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
KHTR.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Knight Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$5.49 |
| 52 Week High | CA$5.54 |
| 52 Week Low | CA$4.07 |
| Beta | 0.040 |
| 1 Month Change | 27.18% |
| 3 Month Change | 28.13% |
| 1 Year Change | 39.09% |
| 3 Year Change | 51.77% |
| 5 Year Change | 30.69% |
| Change since IPO | -0.69% |
Recent News & Updates
Recent updates
Shareholder Returns
| KHTR.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 2.5% | 0.7% | 3.4% |
| 1Y | 39.1% | 43.5% | 29.7% |
Return vs Industry: KHTR.F underperformed the US Pharmaceuticals industry which returned 43.5% over the past year.
Return vs Market: KHTR.F exceeded the US Market which returned 29.7% over the past year.
Price Volatility
| KHTR.F volatility | |
|---|---|
| KHTR.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: KHTR.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine KHTR.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 830 | Samira Sakhia | www.knighttx.com |
Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; Lenvima for advanced renal cell cancer; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Bapoci for brest cancer; Xetrane for multiple myeloma; Rembre for chronic myeloid leukemia; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms; IPX203 for Parkinson’s disease; Qelbree for attention-deficit hyperactivity disorder; Jornay PM for attention-deficit hyperactivity disorder; and Crexon for Parkinson’s disease. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Fibridoner for idiopathic pulmonary fibrosis; Ibsrela for IBS-C; and Exelon for symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease.
Knight Therapeutics Inc. Fundamentals Summary
| KHTR.F fundamental statistics | |
|---|---|
| Market cap | US$534.95m |
| Earnings (TTM) | -US$3.88m |
| Revenue (TTM) | US$325.30m |
Is KHTR.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KHTR.F income statement (TTM) | |
|---|---|
| Revenue | CA$450.09m |
| Cost of Revenue | CA$249.86m |
| Gross Profit | CA$200.23m |
| Other Expenses | CA$205.60m |
| Earnings | -CA$5.37m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 07, 2026
| Earnings per share (EPS) | -0.055 |
| Gross Margin | 44.49% |
| Net Profit Margin | -1.19% |
| Debt/Equity Ratio | 8.8% |
How did KHTR.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/11 00:31 |
| End of Day Share Price | 2026/04/09 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Knight Therapeutics Inc. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tania Armstrong-Whitworth | ATB Cormark Historical (Cormark Securities) |
| David Kideckel | Beacon Securities Limited |
| David Martin | Bloom Burton & Co. |